(Q37947909)

25 August 2017

title

Biological mechanisms and clinical implications of endocrine resistance in breast cancer (English)

1 reference

25 August 2017

1 reference

Mario Giuliano

1

1 reference

25 August 2017

Rachel Schifp

series ordinal

2

1 reference

25 August 2017

C Kent Osborne

series ordinal

3

1 reference

25 August 2017

Meghana V Trivedi

series ordinal

4

1 reference

25 August 2017

language of work or name

1 reference

1 October 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

20 Suppl 3

1 reference

25 August 2017

page(s)

S42-9

1 reference

Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Tamoxifen in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Mechanisms of tamoxifen resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Optimal adjuvant hormonal therapy in postmenopausal women with hormone-receptor-positive early breast cancer: have we answered the question?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Adaptive changes result in activation of alternate signaling pathways and acquisition of resistance to aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Fulvestrant - a novel endocrine therapy for breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Estrogen receptor pathways to AP-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Membrane receptors for steroid hormones: signal transduction and physiological significance

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Establishment of an in vitro estrogen-dependent mouse mammary tumor model: a new tool to understand estrogen responsiveness and development of tamoxifen resistance in the context of stromal-epithelial interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Aromatase inhibitors in breast cancer: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Estrogen receptor mutations in human disease

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Loss of heterozygosity of the oestrogen receptor gene in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity i

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Measurement of steroid hormone receptors in breast cancer patients on tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

The dynamics of estrogen receptor status in breast cancer: re-shaping the paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Genome-wide analysis of estrogen receptor binding sites

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Biological determinants of endocrine resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Activity of fulvestrant in HER2-overexpressing advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Tipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970293-4

7 January 2021

10.1016/S0960-9776(11)70293-4

Identifiers

DOI

1 reference

25 August 2017

1 reference